Financial Data and Key Metrics Changes - Revenue for Q3 2023 was $492.5 million, representing a year-over-year increase of 28.3% [51] - Year-to-date revenue for the nine months ended September 30, 2023, was $1.39 billion, an increase of 30.2% from the prior year [54] - EBITDA for Q3 2023 was $90.2 million, a 1% increase compared to $89.3 million in Q3 2022 [54] - Net income for Q3 2023 was $70.6 million, up 6.9% from $66 million in the prior year [55] - EBITDA margin for Q3 2023 was 18.3%, down from 23.3% in the prior year [52] Business Line Data and Key Metrics Changes - Net new business awards entering backlog in Q3 increased 29.9% year-over-year to $611.5 million, resulting in a net book-to-bill ratio of 1.24 [51] - Ending backlog as of September 30, 2023, was approximately $2.7 billion, an increase of 20.3% from the prior year [58] Market Data and Key Metrics Changes - Customer concentration: Top 5 customers represent roughly 23% and Top 10 customers represent about 29% of year-to-date total revenue [56] - Cash flow from operating activities in Q3 was $114.4 million, with net days sales outstanding at negative 42.2 days [56] Company Strategy and Development Direction - The company plans to continue investing in organic growth, with increased capital expenditures related to the expansion of its headquarters in Cincinnati [45] - The company is focusing on share repurchases opportunistically, depending on execution levels [45] Management's Comments on Operating Environment and Future Outlook - Management noted a strong business environment with record levels of RFPs and awards, despite challenges in the biotech sector [79] - The company does not expect significant margin expansion in 2024 due to ongoing wage and benefit inflation [84] Other Important Information - Full year 2023 revenue guidance is expected to be in the range of $1.87 billion to $1.89 billion, representing growth of 28.1% to 29.5% over 2022 [61] - Initial guidance for 2024 expects revenue in the range of $2.15 billion to $2.2 billion [66] Q&A Session Summary Question: Can you comment on the funding environment and its impact? - Management indicated that while there are funding challenges, they are able to find opportunities among well-funded biotech companies [71][73] Question: What is the outlook for pass-through costs? - Management noted that elevated pass-through costs are broad-based and not concentrated in any one study, with metabolic studies contributing significantly [82][86] Question: How is the company addressing the current business environment? - Management stated that they have pivoted to a different subset of small biotech with funded programs, allowing them to find opportunities despite the challenges [73] Question: What are the expectations for 2024 EBITDA margins? - Management does not expect significant margin expansion in 2024 due to ongoing inflationary pressures [84]

1.38x 1.49x 17.7% 17.6% 1.28x 1.28x 1.23x 1.23x 1.28x 1.25x 17.0% 16.7% 16.6% 16.8% 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 Net New Business Awards ($ in millions) MAKING THE COMPLEX SEAMLESS Q2 2023 – KEY FINANCIAL HIGHLIGHTS A. See the appendix for the non-GAAP reconciliation of the EBITDA calculations. B. Net income per diluted share for 2Q23 and 2Q22 excludes $0.041 million and $0.031 million, respectively, in undistributed earnings allocated to RSAs. Net income p ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 ______________ ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q2 2023 Earnings Conference Call July 25, 2023 9:00 AM ET Company Participants Lauren Morris - Director, IR August Troendle - CEO Jesse Geiger - President Kevin Brady - CFO Conference Call Participants David Windley - Jefferies Max Smock - William Blair Sandy Draper - Guggenheim Partners Operator Good day, ladies and gentlemen, and welcome to the Medpace's Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we wi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 _____________ ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2023 Earnings Conference Call April 25, 2023 9:00 AM ET Company Participants Lauren Morris - IR August Troendle - CEO Jesse Geiger - President Kevin Brady - CFO Conference Call Participants David Windley - Jefferies Max Smock - William Blair Sandy Draper - Guggenheim Partners John Sourbeer - UBS Operator Good day, ladies and gentlemen, and welcome to the Medpace First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. Late ...

FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results and the effective tax rate used for non-GAAP adjustment purposes. In this context, forward-lookin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ FORM 10-K ________________________________________________________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or _________________________________________________________ ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q4 2022 Earnings Conference Call February 14, 2023 9:00 AM ET Company Participants Lauren Morris - IR August Troendle - CEO Jesse Geiger - President Kevin Brady - CFO Conference Call Participants Sandy Draper - Guggenheim Partners Max Smock - William Blair David Windley - Jefferies John Sourbeer - UBS Eric Coldwell - RW Baird Operator Good day, ladies and gentlemen, and welcome to the Medpace Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all p ...

| --- | --- | |-------|-------| | | | | | | | | | This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results and the effective tax rate used for non-GAAP adjustment purposes. In this context, forward-looking state ...